Login

Financial Snapshot

Revenue
TTM
$10.02M
Gross Margin
TTM
62.48%
Net Income
TTM
-$90.50M
Current Assets
2025 Q4
$61.21M
Current Liabilities
2025 Q4
$48.96M
Current Ratio
2025 Q4
125.03%
Total Assets
2025 Q4
Total Liabilities
2025 Q4
Book Value
2025 Q4
49.16M
Cash
2025 Q4
$22.13M
P/E
Last 4 Quarters
N/A
Free Cash Flow
TTM
-$70.30M

Stock Price

Loading...
Market Cap: $113.52 Million

About Nyxoah SA

Nyxoah SA is a medical technology company, which engages in the development and commercialization of solutions to treat Obstructive Sleep Apnea (OSA). The company is headquartered in Mont-Saint-Guibert, Brabant-Wallon and currently employs 154 full-time employees. The company went IPO on 2020-09-18. The firm focuses on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The system consists of a neurostimulator, which is implanted close to the nerve of the tongue, as well as an activation chip, which is connected to a disposable patch and is positioned every night by the patient under the chin.

Industry: Surgical & Medical Instruments & Apparatus Peers: REMEDENT, INC.

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support